Does automated insulin delivery improve glucose control in children under 7 with type 1 diabetes?

A 2026 meta-analysis reported improved time in range and HbA1c compared with standard care over 8 to 16 weeks.

Meta-analysis · Diabetic Medicine 2026

Reference: Lin Q, Zhou Y, Lei M, et al. Diabet Med. 2026;43(7):e70354. doi:10.1111/dme.70354. PMID:42108409. https://pubmed.ncbi.nlm.nih.gov/42108409/

Chapters

0:00 Intro

0:38 The study

3:01 What this means

3:31 Outro

Read the structured trial summary at https://hormoneinsight.com/

AI-narrated. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

Apple App Store: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Google Play: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does liraglutide reduce hospitalization risk compared with glimepiride in people with type 2 diabetes on metformin?

In GRADE participants with type 2 diabetes on metformin, time to first hospitalization did not differ overall by glucose-lowering drug; liraglutide modestly reduced subsequent hospitalization risk versus glimepiride on assigned treatment.

Secondary analysis of a randomised trial · Diabetes Care 2025

Reference: Hsia DS, Younes N, Ghosh A. Diabetes Care. 2025. PMID: 40424051. https://pubmed.ncbi.nlm.nih.gov/40424051/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en

Does tirzepatide improve kidney outcomes compared with insulin glargine in type 2 diabetes with high cardiovascular risk?

In people with type 2 diabetes and high cardiovascular risk, tirzepatide slowed eGFR decline and reduced albuminuria more than insulin glargine over a median 85 weeks. This was a secondary analysis of a randomised trial.

Reference: Heerspink HJL, Sattar N, Pavo I, et al. Lancet Diabetes Endocrinol. 2022. PMID: 36152639. https://pubmed.ncbi.nlm.nih.gov/36152639/

AI-narrated episode. For healthcare professionals; educational only and not medical advice.

Hormone Insight: https://hormoneinsight.com/

iPhone/iPad app: https://apps.apple.com/sa/app/hormone-insight/id6749515856

Android app: https://play.google.com/store/apps/details?id=com.fahadwali78.hormoneinsightmobile&hl=en